Sign up to save your podcasts
Or
Share Aubrey de Grey On Why Everything You Think About Aging Is Wrong
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Aubrey de Grey On Why Everything You Think About Aging Is Wrong
Sponsor: Fatty15
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.
Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED
______________________
Guests: Dr. Aubrey de Grey
President and CSO at LEV Foundation
Linkedin: www.linkedin.com/in/aubrey-de-grey-24260b/
Website: www.levf.org/
______________________
What if aging is not inevitable… but something we can actively manage?
Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.
Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.
Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.
In this episode, you’ll learn:
- How intrinsic capacity and resilience can measure functional aging earlier than traditional methods
- Why preventative medicines face societal and regulatory barriers
- How high-profile advocates and clinics are shaping public acceptance of longevity therapies
- Ethical and practical considerations for equitable access worldwide
- Where Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040
If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.
Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
______________________
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
View all episodes
By Longevity.TechnologySponsor: Fatty15
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.
Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED
______________________
Guests: Dr. Aubrey de Grey
President and CSO at LEV Foundation
Linkedin: www.linkedin.com/in/aubrey-de-grey-24260b/
Website: www.levf.org/
______________________
What if aging is not inevitable… but something we can actively manage?
Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.
Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.
Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.
In this episode, you’ll learn:
- How intrinsic capacity and resilience can measure functional aging earlier than traditional methods
- Why preventative medicines face societal and regulatory barriers
- How high-profile advocates and clinics are shaping public acceptance of longevity therapies
- Ethical and practical considerations for equitable access worldwide
- Where Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040
If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.
Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
______________________
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn